Restless Legs Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

RLS MCID: RST001 MIFTS: 51	Restless Legs Syndrome (RLS) Categories: Mental diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Restless Legs Syndrome

MalaCards integrated aliases for Restless Legs Syndrome:

Name: Restless Legs Syndrome ¹¹ ¹⁹ ⁴² ⁵² ⁷⁵ ⁵³ ⁴³ ¹⁴ ⁶³ ¹⁶ ⁷¹ ³³

Restless Leg Syndrome ¹⁹ ⁴²

Willis-Ekbom Disease ¹¹ ⁴²

Ekbom Syndrome ⁴² ³³

Wed ¹¹ ⁴²

Restless Legs Syndrome, Susceptibility to ³⁸

Wittmaack-Ekbom Syndrome ¹¹

Willis Ekbom Disease ¹⁹

Ekbom's Syndrome ⁴²

Restless Legs ⁴¹

Rls ⁴²

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Sleep-wake disorders

Sleep-related movement disorders

Restless legs syndrome

External Ids:

Disease Ontology ¹¹ DOID:0050425

ICD9CM ³⁴ 333.94

MeSH ⁴³ D012148

NCIt ⁴⁹ C84501

SNOMED-CT ⁶⁸ 32914008

EFO ¹⁶ EFO_0004270

ICD11 ³³ 1254916765

UMLS ⁷¹ C0035258

Sources

Summaries for Restless Legs Syndrome

MedlinePlus Genetics: ⁴² Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep.The signs and symptoms of restless legs syndrome range from mild to severe; people with mild cases may experience symptoms a few times a month, while those with more severe cases may have symptoms every night. In severe cases, the uncomfortable feelings can affect the arms or other parts of the body in addition to the legs.Many people with restless legs syndrome also experience uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. When these movements occur during sleep, they are called periodic limb movements of sleep (PLMS); when they occur while a person is awake, they are called periodic limb movements of wakefulness (PLMW). It is unclear whether PLMS and PLMW are features of restless legs syndrome itself or represent similar, but separate, conditions.Restless legs syndrome and PLMS can affect the quality and amount of sleep. As a result of these conditions, affected individuals may have difficulty concentrating during the day, and some develop mood swings, depression, or other health problems.Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45, and sometimes as early as childhood. The signs and symptoms of this form usually worsen slowly with time. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly.

MalaCards based summary: Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 7 and restless legs syndrome 6, and has symptoms including tremor, back pain and headache. An important gene associated with Restless Legs Syndrome is RLS4 (Restless Legs Syndrome 4), and among its related pathways/superpathways are Alpha-synuclein signaling and Methylphenidate Pathway, Pharmacodynamics. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and spinal cord.

MedlinePlus: ⁴¹ Restless legs syndrome (RLS) causes a powerful urge to move your legs. Your legs become uncomfortable when you are lying down or sitting. Some people describe it as a creeping, crawling, tingling, or burning sensation. Moving makes your legs feel better, but not for long. RLS can make it hard to fall asleep and stay asleep. In most cases, there is no known cause for RLS. In other cases, RLS is caused by a disease or condition, such as anemia or pregnancy. Some medicines can also cause temporary RLS. Caffeine, tobacco, and alcohol may make symptoms worse. Lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. If those don't work, medicines may reduce the symptoms of RLS. Most people with RLS also have a condition called periodic limb movement disorder (PLMD). PLMD is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. PLMD and RLS can also affect the arms. NIH: National Heart, Lung, and Blood Institute

GARD: ¹⁹ Restless legs syndrome (RLS) is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. Movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. Many people with Restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. RLS likely results from a combination of genetic and environmental factors, many of which are unknown. The syndrome may also be classified in several types (RLS1, RLS2, RLS3, RLS4, RLS5, RLS6, RLS7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility) to have the syndrome.

PubMed Health : ⁶³ Restless legs syndrome: Restless legs syndrome (RLS) is a disorder that causes a strong urge to move your legs. This urge to move often occurs with strange and unpleasant feelings in your legs. Moving your legs relieves the urge and the unpleasant feelings. People who have RLS describe the unpleasant feelings as creeping, crawling, pulling, itching, tingling, burning, aching, or electric shocks. Sometimes, these feelings also occur in the arms. The urge to move and unpleasant feelings happen when you're resting and inactive. Thus, they tend to be worse in the evening and at night.

NINDS: ⁵² Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, pulling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

Disease Ontology: ¹¹ A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

Wikipedia: ⁷⁵ Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is generally a long-term... more...

Sources

Related Diseases for Restless Legs Syndrome

Diseases in the Restless Legs Syndrome family:

Restless Legs Syndrome 1	Restless Legs Syndrome 2
Restless Legs Syndrome 3	Restless Legs Syndrome 4
Restless Legs Syndrome 6	Restless Legs Syndrome 5
Restless Legs Syndrome 7	Restless Legs Syndrome 8

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 537)

#	Related Disease	Score	Top Affiliating Genes
1	restless legs syndrome 7	33.4	RLS7 MEIS1
2	restless legs syndrome 6	33.4	RLS6 BTBD9
3	periodic limb movement disorder	32.6	SLC6A3 SKOR1 HCRT DRD2 BTBD9
4	sleep disorder	32.4	SLC6A3 MAOB HCRT
5	movement disease	32.3	SLC6A3 MAOB DRD3 DRD2
6	attention deficit-hyperactivity disorder	31.9	SLC6A3 PTPRD MAOB HCRT DRD3 DRD2
7	migraine with or without aura 1	31.8	SLC6A3 MAOB HCRT DRD3 DRD2
8	anxiety	31.5	SLC6A3 MAOB HCRT DRD3 DRD2
9	parkinsonism	31.5	SLC6A3 MAOB DRD3 DRD2
10	rem sleep behavior disorder	31.5	SLC6A3 MAOB HCRT
11	major depressive disorder	31.4	SLC6A3 MAOB HCRT DRD3 DRD2
12	essential tremor	31.4	SLC6A3 SKOR1 DRD3
13	mood disorder	31.4	SLC6A3 MAOB HCRT DRD3 DRD2
14	pathological gambling	31.3	SLC6A3 MAOB DRD3 DRD2
15	impulse control disorder	31.3	SLC6A3 MAOB DRD3 DRD2
16	bruxism	31.3	HCRT DRD3 DRD2
17	multiple system atrophy 1	31.3	SLC6A3 MAOB DRD2
18	eating disorder	31.2	SLC6A3 HCRT DRD2
19	gilles de la tourette syndrome	31.2	SLC6A3 DRD3 DRD2 BTBD9
20	psychotic disorder	31.1	TFRC SLC6A3 MAOB DRD3 DRD2
21	supranuclear palsy, progressive, 1	31.1	SLC6A3 MAOB HCRT DRD2
22	tic disorder	31.0	SLC6A3 DRD3 DRD2 BTBD9
23	personality disorder	31.0	SLC6A3 MAOB DRD3 DRD2
24	obsessive-compulsive disorder	31.0	SLC6A3 PTPRD MAOB DRD3 DRD2
25	dystonia	30.9	SLC6A3 MAOB HCRT DRD3 DRD2
26	tobacco addiction	30.9	SLC6A3 DRD3 DRD2
27	withdrawal disorder	30.9	SLC6A3 HCRT DRD2
28	dementia, lewy body	30.9	SLC6A3 MAOB HCRT
29	substance abuse	30.8	SLC6A3 HCRT DRD3 DRD2
30	dysthymic disorder	30.7	SLC6A3 HCRT
31	oppositional defiant disorder	30.7	SLC6A3 DRD3 DRD2
32	kleptomania	30.6	SLC6A3 DRD2
33	huntington disease	30.6	SLC6A3 MAOB HCRT DRD2
34	alcohol use disorder	30.6	SLC6A3 DRD3 DRD2
35	opiate dependence	30.6	SLC6A3 HCRT DRD3 DRD2
36	post-traumatic stress disorder	30.6	SLC6A3 MAOB HCRT DRD2
37	drug dependence	30.6	SLC6A3 DRD3 DRD2
38	delusional disorder	30.6	SLC6A3 DRD2
39	restless legs syndrome 2	11.8
40	restless legs syndrome 1	11.8
41	restless legs syndrome 3	11.7
42	restless legs syndrome 4	11.7
43	restless legs syndrome 5	11.7
44	restless legs syndrome 8	11.7
45	iron metabolism disease	11.2
46	l-ferritin deficiency	11.2
47	parkinson disease, late-onset	11.0
48	end stage renal disease	10.9
49	neuropathy	10.9
50	polyneuropathy	10.8

Graphical network of the top 20 diseases related to Restless Legs Syndrome:

Sources

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:

tremor; back pain; headache; syncope; excessive daytime somnolence; pain; chronic pain; sciatica; snoring; sleep disturbances; seizures; vertigo/dizziness; sleeplessness

Sources

Drugs & Therapeutics for Restless Legs Syndrome

PubMed Health treatment related to Restless Legs Syndrome: ⁶³

Restless legs syndrome (RLS) has no cure. If a condition or medicine triggers RLS, it may go away or get better if the trigger is relieved or stopped. RLS can be treated. The goals of treatment are to: Prevent or relieve symptoms Increase the amount of sleep you're getting and improve the quality of your sleep Treat or correct any underlying condition that may trigger or worsen RLS Mild cases of RLS often are treated with lifestyle changes and sometimes with periodic use of medicines. More severe RLS usually is treated with daily medicines.

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Diphenhydramine

Approved, Investigational

Phase 4

147-24-0, 58-73-1

3100

Suvorexant

Approved, Investigational

Phase 4

1030377-33-3

57505028 24965990

Promethazine

Approved, Investigational

Phase 4

60-87-7

4927

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Levetiracetam

Approved

Phase 4

102767-28-2

441341 5284583

Topiramate

Approved

Phase 4

97240-79-4

5284627

Amitriptyline

Approved

Phase 4

50-48-6

2160

Valproic acid

Approved, Investigational

Phase 4

99-66-1

3121

Rizatriptan

Approved

Phase 4

145202-66-0, 144034-80-0

5078

Rivastigmine

Approved, Investigational

Phase 4

123441-03-2

77991

Memantine

Approved, Investigational

Phase 4

41100-52-1, 19982-08-2

4054

Duloxetine

Approved

Phase 4

136434-34-9, 116539-59-4

60835

Donepezil

Approved

Phase 4

120014-06-4

3152

Lamotrigine

Approved, Investigational

Phase 4

84057-84-1

3878

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Zolmitriptan

Approved, Investigational

Phase 4

139264-17-8

60857

Sumatriptan

Approved, Investigational

Phase 4

103628-46-2

5358

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Propranolol

Approved, Investigational

Phase 4

318-98-9, 525-66-6

62882 4946

Apomorphine

Approved, Investigational

Phase 4

41372-20-7, 58-00-4

6005

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Hypoglycemic Agents

Phase 4

Hypnotics and Sedatives

Phase 4

Orexin Receptor Antagonists

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Iron Supplement

Phase 4

Omega 3 Fatty Acid

Phase 4

Gastrointestinal Agents

Phase 4

Emetics

Phase 4

Neurotransmitter Agents

Phase 4

Dopamine agonists

Phase 4

Dopamine Agents

Phase 4

Antiparkinson Agents

Phase 4

Antioxidants

Phase 4

Protective Agents

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Cardiotonic Agents

Phase 4

Sympathomimetics

Phase 4

Benserazide

Approved, Investigational

Phase 3

322-35-0

2327

Levodopa

Approved

Phase 3

59-92-7, 63-84-3

6047

Cabergoline

Approved

Phase 3

81409-90-7

54746

Lisuride

Approved, Investigational

Phase 3

18016-80-3

28864

Bupropion

Approved

Phase 2, Phase 3

31677-93-7, 34841-39-9, 34911-55-2

444

Interventional clinical trials:

(show top 50) (show all 203)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System	Unknown status	NCT02424695	Phase 4	Gabapentin Enacarbil (GEn);Placebo
2	A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep	Completed	NCT00373542	Phase 4	ropinirole CR-RLS
3	Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS	Completed	NCT02025608	Phase 4	Pramipexole;Placebo
4	A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome	Completed	NCT00375284	Phase 4	Pramipexole
5	Post-marketing Clinical Study of Gabapentin Enacarbil -Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment-	Completed	NCT01981941	Phase 4	Gabapentin enacarbil
6	Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome.	Completed	NCT03053427	Phase 4	Placebo;Gabapentin enacarbil
7	A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome	Completed	NCT01976871	Phase 4	Rotigotine
8	A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period	Completed	NCT00472199	Phase 4	Pramipexole;Placebo
9	A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances	Completed	NCT00356096	Phase 4	pramipexole
10	A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome	Completed	NCT00349531	Phase 4	Pramipexole
11	A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome.	Completed	NCT00329602	Phase 4	Placebo;Ropinirole
12	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS)	Completed	NCT00200941	Phase 4	Topiramate
13	Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy	Completed	NCT01245777	Phase 4	ferric carboxymaltose
14	Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome	Completed	NCT01455012	Phase 4	Rotigotine;Placebo
15	Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study	Completed	NCT01823770	Phase 4	Rotigotine;Placebo patchs
16	Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in Treatment of Moderate-to-Severe Primary RLS	Completed	NCT01668667	Phase 4	GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
17	An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose	Completed	NCT00344994	Phase 4	pramipexole
18	A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome	Recruiting	NCT02633683	Phase 4	HORIZANT 600 mg
19	Open Label Assessment of Pitolisant (Wakix) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome	Recruiting	NCT05581576	Phase 4	Pitolisant
20	Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease	Recruiting	NCT03082755	Phase 4	Gabapentin Enacarbil;Placebo Oral Tablet
21	Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia: A Randomized Placebo-Controlled Crossover Trial	Recruiting	NCT04706091	Phase 4	Suvorexant
22	Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record	Enrolling by invitation	NCT02670161	Phase 4	Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
23	Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder	Enrolling by invitation	NCT04610827	Phase 4	Ferrous sulfate
24	Open Label and Placebo-Controlled Assessment of Sublingual Apomorphine (Kynmobi) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome	Not yet recruiting	NCT05529095	Phase 4	Apomorphine Sublingual Film;Placebo
25	Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy: A Key to Improving Sleep and Gait Performance	Not yet recruiting	NCT05003648	Phase 4	Pramipexole;Placebo
26	A Randomized Controlled Trial of Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients	Terminated	NCT03817554	Phase 4	Pramipexole
27	Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome	Terminated	NCT02117076	Phase 4	Gabapentin immediate release;Gabapentin enacarbil extended release
28	Butrans for Treatment of Restless Legs Syndrome	Withdrawn	NCT02138357	Phase 4	buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
29	Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome	Withdrawn	NCT00584246	Phase 4	Pregabalin (Lyrica);Placebo
30	Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome	Withdrawn	NCT03063190	Phase 4	Vitamin D;Placebo Oral Tablet
31	Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial	Unknown status	NCT02256215	Phase 2, Phase 3	Vitamin D
32	Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome	Completed	NCT00144209	Phase 3	pramipexole;levodopa in combination with benserazide
33	Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance	Completed	NCT00748098	Phase 3	GSK1838262 Extended Release Tablets;Placebo
34	A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)	Completed	NCT00363857	Phase 3	Ropinirole
35	A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany	Completed	NCT00357097	Phase 3	Ropinirole
36	A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)	Completed	NCT00314860	Phase 3	ropinirole Extended Release (XR)
37	A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients With Restless Legs Syndrome (RLS)	Completed	NCT00256854	Phase 3	Ropinirole IR 1 mg;Ropinirole IR 2 mg;Ropinirole IR 1 mg Placebo;Ropinirole IR 2 mg Placebo;Ropinirole CR 2 mg;Ropinirole CR 3 mg;Ropinirole CR 2 mg Placebo;Ropinirole CR 3 mg Placebo
38	Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome	Completed	NCT00806026	Phase 3	placebo and pregabalin;pramipexol;Pregabalin
39	An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome	Completed	NCT00498108	Phase 3	Rotigotine
40	Sequential Compression Devices for Treatment of Restless Legs Syndrome - a Prospective, Randomized, Sham-Controlled Study	Completed	NCT00479531	Phase 3
41	A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study	Completed	NCT00390689	Phase 3	Pramipexole 0.125 mg tablet;Pramipexole 0.5 mg tablet
42	DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS Trial): A Randomized Controlled Trial	Completed	NCT03806530	Phase 3	Gabapentin;Ropinirole;Placebo Gabapentin;Placebo Ropinirole
43	A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks	Completed	NCT00654498	Phase 3	Pramipexole;Placebo
44	Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients	Completed	NCT02658188	Phase 3	ASP8825
45	A Double-blind, Placebo-controlled, Randomised Withdrawal Study of 3 Month Duration in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)	Completed	NCT00152958	Phase 3	Pramipexole
46	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome	Completed	NCT00135993	Phase 3	Rotigotine
47	A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks	Completed	NCT00133198	Phase 3	Pramipexole
48	Efficacy of Vitamin C, Vitamin E and Their Combination for Treatment of Restless Legs Syndrome in Hemodialysis Patients: a Randomized Double-blind, Placebo-controlled Trial	Completed	NCT01125033	Phase 2, Phase 3	Vitamin C & Vitamin E;Vitamin C;Vitamin E;Vitamin C Placebo & Vitamin E Placebo
49	A Double-blind, Randomized, Placebo-controlled Multicenter Efficacy Study for the Treatment of Patients With Restless Legs Syndrome (RLS)	Completed	NCT00627003	Phase 3	Cabergoline
50	A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome	Completed	NCT00991276	Phase 3	pregabalin;placebo;pramipexole

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carbamazepine

Clonazepam

Cochrane evidence based reviews: restless legs syndrome

Sources

Genetic Tests for Restless Legs Syndrome

Sources

Anatomical Context for Restless Legs Syndrome

Organs/tissues related to Restless Legs Syndrome:

MalaCards : Heart, Lung, Spinal Cord, Cingulate Cortex, Kidney, Brain, Cortex

Sources

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 5432)

#	Title	Authors	PMID	Year
1	Uncovering the mechanism of Radix Paeoniae Alba in the treatment of restless legs syndrome based on network pharmacology and molecular docking. ⁶² ⁴¹	Liu J...Wang T	36401463	2022
2	Explainable Machine-Learning-Based Characterization of Abnormal Cortical Activities for Working Memory of Restless Legs Syndrome Patients. ⁶² ⁴¹	Kim M...Kim KH	36298144	2022
3	Association Of Bone Mineral Profile With Restless Leg Syndrome In Patients With End Stage Renal Disease. ⁶² ⁴¹	Sultan S...Ahmad A	36414586	2022
4	Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome. ⁵³ ⁶²	Baier PC...Hallschmid M	19013101	2009
5	Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. ⁵³ ⁶²	Poceta JS...Kripke DF	18207455	2009
6	Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. ⁵³ ⁶²	Reimold M...Burk K	16941469	2006
7	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. ⁵³ ⁶²	Cervenka S...Farde L	16816393	2006
8	Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. ⁵³ ⁶²	Earley CJ...Allen RP	16268375	2005
9	CSF iron, ferritin and transferrin levels in restless legs syndrome. ⁵³ ⁶²	Mizuno S...Horiguchi J	15743333	2005
10	Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. ⁵³ ⁶²	Connor JR...Allen RP	15136682	2004
11	Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. ⁵³ ⁶²	Berger K...Weiland SK	12242538	2002
12	Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. ⁵³ ⁶²	Allen RP...Earley CJ	12196669	2002
13	Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. ⁵³ ⁶²	Earley CJ...Allen RP	10762522	2000
14	Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms. ⁵³ ⁶²	Dimmitt SB...Riley GJ	10724062	2000
15	Sex modulates the outcome of subthalamic nucleus deep brain stimulation in patients with Parkinson's disease. ⁶²	Yuan TS...Zhang JG	36204861	2023
16	Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder. ⁶²	DelRosso LM...Picchietti DL	36265207	2022
17	Prevalence of obstructive sleep apnea as assessed by polysomnography in psychiatric patients with sleep-related problems. ⁶²	Okada I...Ozaki N	35029795	2022
18	Prospective evaluation of sleep disturbances in chronic pancreatitis and its impact on quality of life: a pilot study. ⁶²	Ahmed A...Sheth SG	34981297	2022
19	Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome? ⁶²	Suzuki S...Hirata K	36306631	2022
20	The incidence, complications, and treatment of iron deficiency in pregnancy. ⁶²	Benson AE...Lo JO	36153674	2022
21	Restless legs syndrome in patients with psoriasis: association with inflammation and sleep quality. ⁶²	Solak B...Yaldiz M	36468846	2022
22	Association between clinical outcomes and restless legs syndrome in Japanese patients with ulcerative colitis. ⁶²	Kitakata S...Hiasa Y	35852410	2022
23	Restless legs syndrome and cognitive function among adults: a systematic review and meta-analysis. ⁶²	Wang S...Shang H	36472687	2022
24	Neuroanatomy and Functional Connectivity in Patients with Parkinson's Disease with or without Restless Legs Syndrome. ⁶²	Zang QL...Miao W	35999489	2022
25	Usefulness of electronic stimulation in restless legs syndrome: a pilot study. ⁶²	Cho YW...Kim KT	33487095	2022
26	Does physical activity timing differentially correlate with symptoms of restless legs syndrome in adults with multiple sclerosis? ⁶²	Cederberg KLJ...Motl RW	36049405	2022
27	Possible association between vitamin B12 deficiency and restless legs syndrome. ⁶²	Geng C...Zhang H	36401952	2022
28	Effects of aromatherapy massage on the severity of restless legs syndrome in hemodialysis patients: A randomized clinical trial. ⁶²	Amrollahi A...Nasiriani K	35060333	2022
29	Prevalence of sleep disorders in a large French cohort of aircrew members and risk of in-flight sleepiness. ⁶²	Monin J...Manen O	36087520	2022
30	Intravenous iron therapy in the pediatric sleep clinic: a single institution experience. ⁶²	Ingram DG...Sharma M	35912699	2022
31	Cognitive strategies to improve symptoms of restless legs syndrome. ⁶²	Chenini S...Dauvilliers Y	36447357	2022
32	Noninvasive Vagus Nerve Stimulation: A New Therapeutic Approach for Pharmacoresistant Restless Legs Syndrome. ⁶²	Hartley S...Azabou E	36400697	2022
33	Vitamin D deficiency and restless legs syndrome during pregnancy: walking in sunshine? ⁶²	Lee KA...Zak RS	36377836	2022
34	Polysomnographic features of idiopathic restless legs syndrome: a systematic review and meta-analysis of 13 sleep parameters and 23 leg movement parameters. ⁶²	Zhang H...Tang X	35903949	2022
35	Further Studies on the Role of BTBD9 in the Cerebellum, Sleep-like Behaviors and the Restless Legs Syndrome. ⁶²	Lyu S...Li Y	36244636	2022
36	Restless legs syndrome due to brainstem stroke: A systematic review. ⁶²	Kalampokini S...Bargiotas P	36063288	2022
37	The prevalence and associated factors of seasonal exacerbation of subjective symptoms in Japanese patients with restless legs syndrome. ⁶²	Sato M...Inoue Y	36442422	2022
38	Pagophagia and restless legs syndrome are highly associated with iron deficiency and should be included in histories evaluating anemia. ⁶²	Achebe MO...Auerbach M	36322094	2022
39	Restless Legs Syndrome and the Eyes: Spectral-Domain Optic Coherence Tomography Study. ⁶²	Can Usta N...Gunay BO	35238834	2022
40	The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factors. ⁶²	Hengel H...Schols L	36324033	2022
41	Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. ⁶²	Schrag A...Holstiege J	36342675	2022
42	More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea. ⁶²	Verbraecken J	36101923	2022
43	Prevalence of sleep disorders in children with chronic kidney disease: a meta-analysis. ⁶²	Kang KT...Chang RE	35445975	2022
44	Study Protocol: Sleep Effects on Poststroke Rehabilitation Study. ⁶²	Klingman KJ...Fulk GD	35948301	2022
45	Sleep microstructure and clinical characteristics of patients with restless legs syndrome. ⁶²	Amirifard H...Najafi A	35924664	2022
46	Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum. ⁶²	Ferre S...Ciruela F	36375695	2022
47	Sleep and Stroke: Opening Our Eyes to Current Knowledge of a Key Relationship. ⁶²	Brunetti V...Della Marca G	36190654	2022
48	A longitudinal study of restless legs symptoms among patients with depression. ⁶²	Auvinen P...Mantyselka P	35191781	2022
49	Primary dysmenorrhoea in adolescents and young women: A twin family study of maternal transmission, genetic influence and associations. ⁶²	Aouad P...Champion GD	35754341	2022
50	Longitudinal Studies of Sleep Disturbances in Parkinson's Disease. ⁶²	Xu Z...Pavese N	36018498	2022

Sources

Genes for Restless Legs Syndrome

Genes related to Restless Legs Syndrome (8 elite genes):

(show top 50) (show all 79)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	RLS4	Restless Legs Syndrome 4	Genetic Locus	68.48	MalaCards inferred ³⁹ GeneCards inferred via : Publications Gene name (show sections)
2	RLS1	Restless Legs Syndrome, Susceptibility To	Genetic Locus	68.11	MalaCards inferred ³⁹ GeneCards inferred via : Publications Gene name (show sections)
3	RLS2	Restless Legs Syndrome 2	Genetic Locus	68.11	MalaCards inferred ³⁹ GeneCards inferred via : Publications Gene name (show sections)
4	RLS3	Restless Legs Syndrome 3	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
5	RLS5	Restless Legs Syndrome, Susceptibility To, 5	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
6	RLS6	Restless Legs Syndrome, Susceptibility To, 6	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
7	RLS7	Restless Legs Syndrome 7	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
8	RLS8	Restless Legs Syndrome, Susceptibility To, 8	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
9	BTBD9	BTB Domain Containing 9	Protein Coding	38.91	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
10	MEIS1	Meis Homeobox 1	Protein Coding	27.85	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
11	HCRT	Hypocretin Neuropeptide Precursor	Protein Coding	21.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12196669 19013101 18207455
12	DRD2	Dopamine Receptor D2	Protein Coding	19.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16816393 16941469
13	SKOR1	SKI Family Transcriptional Corepressor 1	Protein Coding	17.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	MAP2K5	Mitogen-Activated Protein Kinase Kinase 5	Protein Coding	17.13	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	PTPRD	Protein Tyrosine Phosphatase Receptor Type D	Protein Coding	16.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	TFRC	Transferrin Receptor	Protein Coding	16.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15136682
17	TOX3	TOX High Mobility Group Box Family Member 3	Protein Coding	16.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	15.23	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	MAOB	Monoamine Oxidase B	Protein Coding	15.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	DRD3	Dopamine Receptor D3	Protein Coding	15.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	DRD1	Dopamine Receptor D1	Protein Coding	14.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	HAMP	Hepcidin Antimicrobial Peptide	Protein Coding	14.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	SNCA	Synuclein Alpha	Protein Coding	14.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	SLC11A2	Solute Carrier Family 11 Member 2	Protein Coding	14.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	DRD4	Dopamine Receptor D4	Protein Coding	14.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	COMT	Catechol-O-Methyltransferase	Protein Coding	14.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	GABRR3	Gamma-Aminobutyric Acid Type A Receptor Subunit Rho3	Protein Coding	14.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	MAOA	Monoamine Oxidase A	Protein Coding	14.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	PCDHA3	Protocadherin Alpha 3	Protein Coding	14.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	FTMT	Ferritin Mitochondrial	Protein Coding	14.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	PRKN	Parkin RBR E3 Ubiquitin Protein Ligase	Protein Coding	13.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	PTH	Parathyroid Hormone	Protein Coding	13.54	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	IREB2	Iron Responsive Element Binding Protein 2	Protein Coding	13.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	CLOCK	Clock Circadian Regulator	Protein Coding	13.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	ACO1	Aconitase 1	Protein Coding	13.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	NOS1	Nitric Oxide Synthase 1	Protein Coding	13.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	EPO	Erythropoietin	Protein Coding	13.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	NPAS2	Neuronal PAS Domain Protein 2	Protein Coding	13.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	CACNA1A	Calcium Voltage-Gated Channel Subunit Alpha1 A	Protein Coding	13.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	13.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	POMC	Proopiomelanocortin	Protein Coding	13.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	FTL	Ferritin Light Chain	Protein Coding	13.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	ATXN3	Ataxin 3	Protein Coding	12.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
44	NTS	Neurotensin	Protein Coding	12.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	ADH1B	Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide	Protein Coding	12.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	FMR1	Fragile X Messenger Ribonucleoprotein 1	Protein Coding	12.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	MAPT	Microtubule Associated Protein Tau	Protein Coding	12.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	GABRA4	Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4	Protein Coding	12.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	SLC1A2	Solute Carrier Family 1 Member 2	Protein Coding	12.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	GLO1	Glyoxalase I	Protein Coding	12.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Restless Legs Syndrome

Sources

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Sources

Pathways for Restless Legs Syndrome

Pathways related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Alpha-synuclein signaling ⁶¹	10.37	SLC6A3 MAOB
2	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	10.29	SLC6A3 MAOB DRD3 DRD2

Sources

GO Terms for Restless Legs Syndrome

Cellular components related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	dopaminergic synapse	GO:0098691	9.26	SLC6A3 DRD2
2	obsolete integral component of presynaptic membrane	GO:0099056	8.8	SLC6A3 PTPRD DRD2

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	modulation of chemical synaptic transmission	GO:0050804	10	PTPRD DRD2 BTBD9
2	behavioral response to cocaine	GO:0048148	9.92	DRD3 DRD2
3	positive regulation of renal sodium excretion	GO:0035815	9.91	DRD3 DRD2
4	response to ethanol	GO:0045471	9.91	SLC6A3 MAOB DRD3 DRD2
5	G protein-coupled receptor internalization	GO:0002031	9.89	DRD3 DRD2
6	negative regulation of synaptic transmission, glutamatergic	GO:0051967	9.88	DRD3 DRD2
7	response to cocaine	GO:0042220	9.88	SLC6A3 DRD3 DRD2
8	negative regulation of cytosolic calcium ion concentration	GO:0051481	9.87	DRD2 DRD3
9	dopamine catabolic process	GO:0042420	9.86	SLC6A3 MAOB
10	phospholipase C-activating dopamine receptor signaling pathway	GO:0060158	9.85	DRD3 DRD2
11	adenohypophysis development	GO:0021984	9.84	SLC6A3 DRD2
12	hyaloid vascular plexus regression	GO:1990384	9.83	SLC6A3 DRD2
13	dopamine uptake involved in synaptic transmission	GO:0051583	9.81	SLC6A3 DRD2
14	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.8	DRD2 DRD3
15	regulation of potassium ion transport	GO:0043266	9.78	DRD2 DRD3
16	synaptic transmission, dopaminergic	GO:0001963	9.77	DRD3 DRD2
17	regulation of dopamine uptake involved in synaptic transmission	GO:0051584	9.76	DRD2 DRD3
18	locomotory behavior	GO:0007626	9.76	SLC6A3 MEIS1 DRD3 DRD2
19	response to histamine	GO:0034776	9.67	DRD2 DRD3
20	acid secretion	GO:0046717	9.62	DRD2 DRD3
21	regulation of biological quality	GO:0065008	9.58	DRD3 DRD2
22	regulation of locomotion involved in locomotory behavior	GO:0090325	9.56	DRD3 DRD2
23	response to iron ion	GO:0010039	9.43	TFRC SLC6A3 DRD2
24	prepulse inhibition	GO:0060134	9.1	SLC6A3 DRD3 DRD2

Molecular functions related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heterocyclic compound binding	GO:1901363	9.56	SLC6A3 DRD2
2	dopamine binding	GO:0035240	9.46	SLC6A3 DRD2
3	dopamine neurotransmitter receptor activity	GO:0004952	8.96	DRD3 DRD2
4	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	8.92	DRD3 DRD2